5 Early Signs of Hepatocellular Carcinoma to Watch for

Have you ever wondered whether subtle changes in your body could be warning signs of a serious liver condition? Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, often develops quietly in its early stages. Because the liver can continue functioning even when disease is present, many people may not notice symptoms until the cancer has progressed. Recognizing the early signs of hepatocellular carcinoma symptoms can play an important role in seeking medical attention sooner.

According to cancer statistics, hepatocellular carcinoma accounts for approximately 75%-85% of primary liver cancer cases worldwide, making it a major health concern. Each year, more than 800,000 new cases of liver cancer are diagnosed globally, and the majority are linked to underlying liver conditions such as chronic hepatitis B or hepatitis C infection, cirrhosis, or long-term liver damage. While HCC can occur without obvious symptoms at first, early detection may improve treatment options and outcomes.

Some early warning signs may seem easy to overlook. Unexplained weight loss, persistent fatigue, reduced appetite, discomfort in the upper right side of the abdomen, or changes in how your body feels day to day can sometimes signal that something is affecting liver health. However, these symptoms are not always caused by cancer and may also appear with other medical conditions.

In this guide, we will explore 5 early signs of hepatocellular carcinoma, explain why they happen, and discuss when these changes may require further medical evaluation. Continue reading to learn what your body may be telling you and how early awareness can make a difference in protecting your liver health.

5 Key Early Symptoms of Hepatocellular Carcinoma

Upper Abdominal Pain or Swelling

Upper abdominal pain or swelling in the context of potential liver cancer often signifies tumor growth stretching the liver’s protective capsule or the accumulation of fluid in the abdomen (ascites). This discomfort is typically felt on the right side, just below the rib cage, where the liver is located. Initially, the pain may be a dull, persistent ache or a feeling of pressure.

As the tumor enlarges, it can press on the thin membrane surrounding the liver, known as Glisson’s capsule, which is rich in nerve endings. The stretching of this capsule is what generates the sensation of pain. In some cases, the tumor itself can become large enough to be felt as a hard lump or mass when pressing on the upper right abdomen. This palpable mass is a significant clinical finding that requires immediate investigation.

Furthermore, abdominal swelling can be a more generalized symptom resulting from advanced liver dysfunction. One primary cause is ascites, the abnormal buildup of fluid in the peritoneal cavity (the space within the abdomen). This occurs for two main reasons related to liver cancer.

First, a compromised liver cannot produce enough albumin, a protein that helps keep fluid within the blood vessels. With low albumin levels, fluid leaks out into surrounding tissues. Second, the tumor can increase pressure within the blood vessels supplying the liver (a condition known as portal hypertension), forcing fluid out into the abdominal cavity. This swelling can cause a feeling of tightness, bloating, and a noticeable increase in abdominal girth, often accompanied by shortness of breath if the fluid pushes up on the diaphragm.

Unexplained Weight Loss

Unexplained weight loss occurs with liver cancer primarily due to a combination of cancer-induced metabolic changes, a significant loss of appetite, and the body’s increased energy expenditure fighting the disease. This condition, often referred to as cancer cachexia, is a complex metabolic syndrome characterized by the progressive loss of both muscle mass and fat tissue.

Unlike simple weight loss from dieting, this wasting process cannot be fully reversed by conventional nutritional support alone. The cancer cells release substances called cytokines, which are inflammatory messengers that alter the body’s normal metabolism. These cytokines can increase the body’s resting energy expenditure, meaning the body burns more calories at rest than it normally would.

This metabolic disruption forces the body to break down its own muscle and fat stores for energy, leading to significant and often rapid weight loss even when a person’s food intake has not changed dramatically. Compounding this issue is the loss of appetite (anorexia) that frequently accompanies liver cancer.

The tumor can press on the stomach, causing a feeling of fullness after eating very little (early satiety), while metabolic changes can also disrupt the brain’s signals for hunger. The combination of burning more energy while taking in fewer calories creates a severe energy deficit that fuels the wasting process.

This symptom is particularly concerning when a person loses 5% or more of their body weight over a period of 6 to 12 months without trying. It is a strong indicator that a serious underlying medical condition, such as cancer, may be present.

Persistent Loss of Appetite or Feeling Full After a Small Meal

A persistent loss of appetite or feeling full after a small meal (early satiety) is caused by both mechanical pressure from the growing tumor and systemic metabolic effects of the cancer. Mechanically, as a hepatocellular carcinoma tumor enlarges, it can physically press on the adjacent stomach. This external pressure reduces the stomach’s capacity to expand when food is consumed, triggering stretch receptors in the stomach wall prematurely.

As a result, the brain receives a signal of fullness much earlier than it normally would, leading the individual to stop eating after consuming only a small amount of food. In more advanced cases, the liver itself can become significantly enlarged (hepatomegaly), further contributing to this compression and discomfort.

Metabolically, the cancer itself can profoundly alter the body’s normal appetite regulation. Tumors release cytokines, such as tumor necrosis factor-alpha (TNF-alpha) and interleukins, which are inflammatory proteins that can act on the hypothalamus – the region of the brain responsible for controlling hunger and satiety. These substances can suppress appetite-stimulating hormones and promote a state of anorexia.

Furthermore, impaired liver function can lead to a buildup of toxins in the bloodstream, which can also contribute to a general feeling of malaise, nausea, and a decreased desire to eat. This combination of physical compression and chemical signaling creates a powerful and persistent loss of appetite, contributing directly to the malnutrition and weight loss often seen in patients with liver cancer.

Jaundice

Jaundice is a medical condition characterized by the yellowing of the skin and the whites of the eyes (sclera), which is a critical warning sign because it indicates significant liver dysfunction or a blockage of the bile ducts. This yellow discoloration is caused by an excessive buildup of a substance called bilirubin in the blood. Bilirubin is a yellow-orange pigment produced during the normal breakdown of red blood cells.

A healthy liver processes bilirubin, making it water-soluble so it can be excreted from the body as a component of bile. When the liver is damaged by cancer or when a tumor physically blocks the bile ducts, this process is disrupted. Bilirubin cannot be properly processed or drained, causing its levels in the bloodstream to rise dramatically.

The appearance of jaundice in the context of other potential liver cancer symptoms is particularly alarming because it often signals that the disease has progressed to a point where liver function is substantially compromised. A tumor located near the major bile ducts can compress or invade them, creating a physical obstruction that prevents bile from flowing out of the liver.

Alternatively, if the cancer has grown extensively throughout the liver, there may not be enough healthy liver tissue left to perform the necessary metabolic task of conjugating and excreting bilirubin. In either scenario, jaundice points to a serious underlying problem. Associated symptoms can include dark-colored urine (as the kidneys try to excrete excess bilirubin) and pale, clay-colored stools (due to the lack of bilirubin reaching the intestines). Jaundice is rarely an early symptom but is a definitive sign that demands immediate medical evaluation.

Persistent Nausea or Vomiting

Persistent nausea or vomiting can occur with Hepatocellular Carcinoma as a result of the liver’s declining ability to filter toxins, the physical effects of fluid buildup (ascites), and the systemic metabolic impact of the cancer. The liver plays a central role in detoxifying the blood by removing harmful substances.

When liver function is impaired by a growing tumor, these toxins, such as ammonia, can accumulate in the bloodstream. Elevated levels of these substances can directly affect the brain, including the chemoreceptor trigger zone, which is responsible for controlling the nausea and vomiting reflex. This chemical imbalance can lead to a constant feeling of queasiness that is not necessarily related to food intake.

Additionally, physical factors can contribute significantly to these symptoms. As mentioned, advanced liver cancer often leads to ascites, the accumulation of fluid in the abdomen. This fluid can exert considerable pressure on the stomach and other digestive organs, leading to feelings of bloating, discomfort, and nausea. This pressure can also slow down the emptying of the stomach, further exacerbating the sensation of fullness and triggering vomiting.

Finally, the cancer itself releases various substances that can disrupt the body’s normal hormonal and metabolic balance. These systemic changes, combined with the general feeling of being unwell (malaise) that accompanies cancer, can make nausea and vomiting persistent and difficult to manage. It reflects a multi-faceted assault on the body’s digestive and metabolic systems driven by the underlying disease.

What is Hepatocellular Carcinoma?

Hepatocellular Carcinoma (HCC) is the most common type of primary liver cancer that originates in the hepatocytes, the main cells of the liver; those most at risk are individuals with chronic liver diseases, particularly cirrhosis, chronic hepatitis B or C infection, and nonalcoholic fatty liver disease. This cancer develops when the DNA of hepatocytes mutates, causing the cells to grow and divide uncontrollably, eventually forming a malignant tumor.

What Exactly Defines Hepatocellular Carcinoma?

Hepatocellular Carcinoma is defined as a primary malignancy of the liver that arises from the uncontrolled proliferation of hepatocytes, the liver’s chief functional cells. This distinction as a “primary” cancer is crucial, as it means the cancer starts within the liver itself, rather than spreading to the liver from another organ (which would be termed metastatic liver cancer or secondary liver cancer).

Hepatocytes constitute about 80% of the liver’s mass and are responsible for a vast array of metabolic functions, including protein synthesis, detoxification of the blood, and production of bile. The development of HCC is almost always preceded by chronic liver injury and inflammation. This persistent damage triggers a continuous cycle of cell death and regeneration.

Over time, this rapid cell turnover increases the likelihood of genetic mutations occurring in the hepatocytes. If these mutations affect genes that control cell growth and division, they can lead to the formation of a cancerous tumor.

The progression from a healthy liver to one with HCC typically follows a well-established path, often starting with chronic inflammation (hepatitis), which leads to the formation of scar tissue (fibrosis), and eventually culminates in severe, irreversible scarring known as cirrhosis. Cirrhosis is the single most significant risk factor, as the disorganized and scarred liver tissue provides an ideal environment for cancerous cells to emerge and thrive.

Therefore, HCC is not a disease that appears suddenly in a healthy liver; it is the end-stage consequence of long-standing liver damage. Its definition is intrinsically linked to the underlying pathology of chronic liver disease.

Common Risk Factors for Developing HCC

The most common risk factors for developing Hepatocellular Carcinoma are chronic viral hepatitis infections (Hepatitis B and C), alcoholic cirrhosis, and nonalcoholic fatty liver disease (NAFLD), which collectively account for the vast majority of cases worldwide. These conditions all lead to the long-term liver inflammation and damage that precipitates cancer.

Chronic Hepatitis B (HBV) and Hepatitis C (HCV) infections are the leading causes of HCC globally. Both viruses can establish a chronic infection in the liver, leading to persistent inflammation. Over decades, this inflammation causes widespread fibrosis and eventually cirrhosis. Importantly, HBV can also directly integrate its genetic material into the host liver cells’ DNA, which can trigger cancerous changes even in the absence of cirrhosis, making it a direct carcinogen.

Cirrhosis, the extensive scarring of the liver, is the strongest predisposing factor for HCC. While viral hepatitis and alcohol are common causes of cirrhosis, any condition that leads to it increases risk. This includes autoimmune hepatitis and inherited metabolic disorders. The constant cycle of damage and regeneration in a cirrhotic liver creates a high-risk environment for mutations.

Chronic, excessive alcohol consumption is a major cause of liver damage. It leads to alcoholic hepatitis and eventually alcoholic cirrhosis. Alcohol and its metabolic byproducts are directly toxic to liver cells, promoting inflammation, oxidative stress, and DNA damage, which significantly elevate the risk of developing HCC.

Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) is a rapidly growing cause of HCC, linked to the global epidemics of obesity, type 2 diabetes, and metabolic syndrome. NAFLD involves the accumulation of excess fat in the liver. In some individuals, this progresses to NASH, which includes inflammation and liver cell damage. Over time, NASH can lead to cirrhosis and subsequently HCC. It is projected to become the leading cause of HCC in many Western countries.

Less common but still significant risk factors include exposure to aflatoxins (toxins produced by certain fungi that can contaminate crops like corn and peanuts), and certain inherited liver diseases such as hemochromatosis (iron overload) and alpha-1 antitrypsin deficiency.

When to Seek Medical Help?

You should consult a doctor about potential liver cancer symptoms if you experience any of the key signs—such as abdominal pain, unexplained weight loss, or jaundice – persistently, especially if you have known risk factors like cirrhosis or chronic hepatitis. Because these symptoms are often non-specific, their duration and context are critically important.

A fleeting symptom is less concerning than one that lasts for several weeks or worsens over time. Immediate medical consultation is essential to determine the underlying cause and to ensure that a serious condition like liver cancer is not overlooked. Below, we clarify whether these symptoms are definitive signs and which combinations require urgent attention.

Are These Symptoms a Definite Sign of Hepatocellular Carcinoma?

No, but their persistence and occurrence in combination should be taken very seriously as a potential indicator of a significant health issue, including liver cancer. The symptoms associated with Hepatocellular Carcinoma such as abdominal pain, weight loss, and nausea are considered non-specific, meaning they can be caused by a wide range of other medical conditions.

For example, upper abdominal pain could be due to gastritis, gallstones, or pancreatitis. Unexplained weight loss can be a symptom of hyperthyroidism, diabetes, or other types of cancer. Jaundice can be caused by benign conditions like Gilbert’s syndrome or a blockage from a gallstone. Therefore, the presence of any single symptom is not, by itself, a definitive sign of liver cancer.

However, the diagnostic importance of these symptoms increases significantly based on several factors. The first is persistence. A symptom that does not resolve within a week or two warrants a medical evaluation.

The second is the combination of symptoms. Experiencing unexplained weight loss along with upper abdominal pain and a loss of appetite is far more concerning than experiencing any one of these alone.

The third, and perhaps most critical, factor is the presence of underlying risk factors. For an individual with known cirrhosis or chronic hepatitis B or C, the new onset of these symptoms is a major red flag that must be investigated promptly to rule out the development of HCC. While these signs are not a guaranteed diagnosis, they are a clear signal that a comprehensive medical workup is necessary.

Combination of Symptoms Requiring Immediate Medical Attention

Any combination of symptoms that suggests rapid or severe liver dysfunction, such as the sudden onset of jaundice accompanied by abdominal pain and significant weight loss, requires immediate medical attention. This trio of symptoms is particularly alarming because it points towards a serious and potentially advanced problem affecting the liver.

Jaundice indicates that the liver is failing to process bilirubin, either due to extensive internal damage or a major blockage of the bile ducts. When this is paired with pain from a growing tumor and the systemic metabolic effects causing weight loss, it creates a clinical picture that cannot be ignored.

Another highly concerning combination is a palpable mass or lump in the upper right abdomen along with any of the other systemic symptoms like fatigue, loss of appetite, or nausea. Discovering a physical mass is a clear indication of an abnormal growth that needs urgent characterization.

Furthermore, any signs of acute complications should trigger an emergency medical response. These include vomiting blood (hematemesis) or having black, tarry stools (melena), which can indicate bleeding from varices (enlarged veins) caused by severe portal hypertension. Sudden, severe abdominal swelling and pain could signal the rupture of a tumor or the rapid accumulation of ascitic fluid.

For individuals with a known history of chronic liver disease, any noticeable deterioration in their condition such as worsening swelling, increasing confusion (a sign of hepatic encephalopathy), or a general decline in health should be treated as a medical emergency. In these situations, time is of the essence, and prompt medical intervention is critical for diagnosis and managing potentially life-threatening complications.

How is Hepatocellular Carcinoma Diagnosis

The official diagnosis of Hepatocellular Carcinoma (HCC) involves a multi-modal approach, integrating blood analysis, sophisticated imaging, and, when necessary, tissue sampling to confirm the presence of cancerous cells. The initial step often involves blood tests, most notably the measurement of alpha-fetoprotein (AFP).

While elevated AFP levels can be a strong indicator of HCC, particularly in patients with known liver disease like cirrhosis, it is not a definitive marker on its own, as some tumors do not produce AFP and other liver conditions can cause it to rise. Consequently, imaging studies are the cornerstone of diagnosis. High-resolution, multiphasic imaging techniques such as a computed tomography (CT) scan or magnetic resonance imaging (MRI) are standard.

These scans use contrast dye to observe blood flow patterns in the liver; HCC tumors typically have a characteristic pattern of rapid arterial blood supply (arterial phase hyperenhancement) followed by a quick washout of the contrast agent in later phases. In many cases, especially for high-risk patients with cirrhosis, these distinct imaging features are sufficient to make a confident diagnosis without a biopsy.

When imaging results are ambiguous or inconclusive, a liver biopsy is performed to provide a definitive diagnosis. A small sample of the suspicious liver tissue is extracted using a needle, a procedure typically guided by ultrasound or CT to ensure precision.

Also, a pathologist then examines the tissue under a microscope to identify malignant hepatocytes, confirming the diagnosis of HCC and sometimes providing information about the tumor’s grade or aggressiveness.

While a biopsy is the gold standard for confirmation, it carries minor risks, such as bleeding or the potential for spreading cancer cells along the needle track (needle tract seeding), which is why it is often avoided if non-invasive methods provide a clear answer.

Different Stages of Liver Cancer

Staging liver cancer is a critical process that determines the extent of the disease and is fundamental to developing an effective treatment plan and predicting a patient’s prognosis. Unlike many other cancers that primarily use the TNM (Tumor, Node, Metastasis) system, Hepatocellular Carcinoma is often staged using specialized systems that also account for the underlying health of the liver.

The most widely used and comprehensive system is the Barcelona Clinic Liver Cancer (BCLC) staging system. This system is preferred because it not only assesses the tumor’s characteristics but also incorporates the patient’s liver function (often measured by the Child-Pugh score) and their overall physical health (performance status).

The BCLC system classifies patients into five stages, from very early (Stage 0) to terminal (Stage D), each corresponding to a specific treatment recommendation. For example, patients in the very early or early stages might be candidates for curative treatments like surgical resection, liver transplantation, or ablation, whereas those in intermediate stages may benefit from therapies like transarterial chemoembolization (TACE).

Patients with advanced-stage disease, where the cancer has spread beyond the liver or into major blood vessels, are typically considered for systemic therapies such as targeted drugs or immunotherapy.

Hepatocellular Carcinoma vs. Metastatic Liver Cancer

A crucial distinction in liver oncology is between Hepatocellular Carcinoma (HCC) and metastatic liver cancer, as they have entirely different origins, cellular biology, and treatment paradigms.

Hepatocellular Carcinoma is a primary liver cancer, meaning it originates from the liver’s own cells, specifically the hepatocytes. It develops as a direct consequence of chronic liver damage, most commonly caused by viral hepatitis (B or C), alcoholic liver disease, or non-alcoholic fatty liver disease (NAFLD). Because the cancer cells are derived from liver tissue, the disease and its treatment are intimately linked to the overall health and function of the liver.

In contrast, metastatic liver cancer is a secondary liver cancer. This means the cancer began in another organ such as the colon, lung, breast, or pancreas and then spread (metastasized) to the liver through the bloodstream or lymphatic system. The tumors found in the liver are not composed of cancerous liver cells; instead, they are made up of cells from the original cancer site.

For example, if colon cancer spreads to the liver, the tumors in the liver are formed by malignant colon cells, not hepatocytes. This fundamental difference is why it is often referred to as colon cancer with liver metastases, not liver cancer.

How to Prevent Hepatocellular Carcinoma

Lifestyle modifications play a significant role in preventing Hepatocellular Carcinoma by targeting its primary risk factors, particularly those related to chronic liver inflammation and damage. Since the vast majority of HCC cases develop in the context of an unhealthy liver, maintaining liver health is the most effective preventive strategy. One of the most impactful measures is preventing and treating chronic viral hepatitis.

The hepatitis B vaccine is a cornerstone of HCC prevention globally, providing lifelong protection against the virus. For those already living with chronic hepatitis B or C, adhering to antiviral treatment regimens can suppress the virus, reduce liver inflammation, and dramatically lower the risk of progressing to cirrhosis and, subsequently, liver cancer.

Another critical lifestyle factor is moderating alcohol consumption. Excessive alcohol intake is a leading cause of alcoholic liver disease and cirrhosis, which significantly elevates HCC risk. Limiting or abstaining from alcohol can halt or even reverse early-stage liver damage and prevent the development of cancer. This is particularly important for individuals who have other risk factors, such as viral hepatitis or obesity, as the combined effects can be synergistic.

Furthermore, addressing the rising epidemic of metabolic syndrome is now central to HCC prevention, as non-alcoholic fatty liver disease (NAFLD) has become a leading cause of liver cancer, even in the absence of cirrhosis.

Maintain a healthy weight as obesity is a primary driver of NAFLD. Achieving and maintaining a healthy body mass index (BMI) through a balanced diet and regular physical activity can prevent or reverse the buildup of fat in the liver, reducing inflammation and the risk of cancer.

Moreover, a diet low in processed foods, saturated fats, and refined sugars, and rich in fruits, vegetables, whole grains, and lean proteins, supports overall metabolic health and protects the liver from steatosis (fatty buildup) and inflammation.

Effectively managing related conditions like type 2 diabetes and high cholesterol is essential, as they are often intertwined with NAFLD and contribute to the progression of liver disease.

FAQs

1. What is the indicator of hepatocellular carcinoma?

The indicators of hepatocellular carcinoma (HCC) can vary depending on the stage of the disease. Early signs may include unexplained weight loss, loss of appetite, ongoing fatigue, discomfort or pain in the upper right abdomen, and a feeling of fullness after eating small amounts.

Some people may also develop jaundice (yellowing of the skin or eyes), abdominal swelling, or worsening liver function. Because early HCC may cause few noticeable symptoms, regular screening is important for people at higher risk.

2. How long can you live with liver cancer?

Life expectancy with liver cancer depends on several factors, including the stage at diagnosis, liver function, overall health, and response to treatment. When hepatocellular carcinoma is found early and treated effectively, some patients may have significantly better outcomes. Advanced liver cancer can be more difficult to treat, but newer therapies have improved survival options for many patients.

3. Where does hepatocellular carcinoma start?

Hepatocellular carcinoma starts in the hepatocytes, which are the main functional cells of the liver. These cells normally help process nutrients, remove toxins, and support important metabolic functions. When genetic changes occur in hepatocytes, uncontrolled growth can develop and form a cancerous tumor.

4. What does liver cancer pain feel like?

Liver cancer pain is often described as a dull ache, pressure, or discomfort in the upper right side of the abdomen, beneath the ribs. Some people may feel pain that spreads to the right shoulder or back. The intensity can vary, and not everyone with liver cancer experiences pain, especially in the early stages.

5. Where does liver cancer first spread?

Hepatocellular carcinoma can spread beyond the liver through blood vessels or lymphatic pathways. Common areas where it may spread include the lungs, bones, lymph nodes, and adrenal glands. The pattern of spread depends on the individual case and the progression of the disease.

6. What is another name for hepatocellular carcinoma?

Another name for hepatocellular carcinoma is liver cell carcinoma or hepatoma. It is the most common type of primary liver cancer, meaning it begins in the liver rather than spreading there from another organ.

7. Who gets hepatocellular carcinoma?

People with chronic liver damage have a higher risk of developing hepatocellular carcinoma. Major risk factors include chronic hepatitis B or hepatitis C infection, cirrhosis, long-term alcohol-related liver disease, certain inherited liver conditions, and metabolic conditions that contribute to liver inflammation and scarring.

8. What is the most common virus causing hepatocellular carcinoma?

The most common viruses linked to hepatocellular carcinoma are hepatitis B virus (HBV) and hepatitis C virus (HCV). Globally, chronic hepatitis B infection is one of the leading causes of HCC, particularly in regions where HBV infection is more common.

Conclusion

Hepatocellular carcinoma can be challenging to detect because its early symptoms may be mild or easily confused with other health issues. However, paying attention to changes such as unexplained weight loss, fatigue, appetite changes, abdominal discomfort, or signs of liver problems can help encourage earlier medical evaluation.

Understanding the 5 early signs of hepatocellular carcinoma is especially important for people with risk factors, including chronic hepatitis infections, cirrhosis, or long-term liver damage. While these symptoms do not always mean cancer, recognizing unusual changes and discussing them with a healthcare professional can support timely diagnosis and treatment.

Regular checkups, liver health monitoring, and awareness of personal risk factors remain key steps in protecting liver health. If you notice persistent or concerning symptoms, seeking medical advice can help determine the cause and identify the right next steps.

References

• American Cancer Society – What Is Liver Cancer?
• British Liver Trust – HCC symptoms
• NHS – Symptoms of liver cancer
• The University of Texas MD Anderson Cancer Center – Liver Cancer Symptoms
• Healthline – What Are the Symptoms of Hepatocellular Carcinoma?
• Healthdirect Australia Limited – Liver cancer
• American Liver Foundation – Hepatocellular Carcinoma
• National Library of Medicine – Symptom Management in Hepatocellular Carcinoma
• Cancer Council – Liver cancer
• Icahn School of Medicine at Mount Sinai – Hepatocellular Carcinoma
• National University Health System – Hepatocellular Carcinoma
• Cleveland Clinic – Hepatocellular Carcinoma (HCC)
• The Johns Hopkins University – Liver Cancer (Hepatocellular Carcinoma)
• National Library of Medicine – Symptoms and symptom clusters in patients with hepatocellular carcinoma and commonly used instruments: An integrated review
• CDC – Liver Cancer Basics